patients, age ranging from 25 to 101 years. Ninety two patients presented in CS. We did not perform Allen's test in any patients, presence of pulse was enough to proceed. We assessed in-hospital complications.
INTRODUCTION Coronary no-reflow during primary PCI is a predictor of poorer cardiovascular outcome. Both endothelial dysfunction and no-reflow involves abnormal vascular function and hemostasis. Therefore, our aim was to assess the association between risk factors, endothelial dysfunction and no reflow during primary PCI.
METHODS Thirty consecutive patients with STEMI and normal flow during primary PCI were compared to 19 consecutive patients who had no reflow. All subjects underwent assessment of endothelial function (reactive hyperemia index-RHI) within 48-72 h post PCI using the EndoPAT device.
RESULTS Age, sex, and frequency of hypertension were similar in both groups. Smokers were less likely to have no-reflow (Table) . Post PCI there was less STsegment resolution in the no-reflow group (48%þ7 vs 81%þ6; p¼0.001). Patients who had no reflow had subsequently lower ejection fraction (39þ10 vs 47þ10; p¼0.015). There was no difference in vascular function (RHI) between groups. (Figure) CONCLUSION Systemic vascular function is not associated with coronary no reflow.
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Abbreviated versus Standard Eptifibatide Infusion in ST Elevation Myocardial Infarction-Outcomes and Predictors of Complications
Alireza Bagherli, Farrukh Hussain, Seeger Shen, Kerrett Wallace, Chris Haye, Steve Promislow University of Manitoba, Winnipeg, MB, Canada BACKGROUND Glycoprotein IIb/IIIa inhibition has been a mainstay in acute myocardial infarction intervention. Major bleeding is a predictor of adverse outcomes in ST elevation myocardial infarction (STEMI).
OBJECTIVES To determine the safety and bleeding outcomes of abbreviated compared to standard infusions of the glycoprotein IIb/IIIa inhibitor eptifibatide in the setting of primary PCI for STEMI.
METHODS
We analyzed a retrospective cohort of 93 STEMI patients who received abbreviated (<18 hours) infusion of eptifibatide and compared them to 91 STEMI patients with standard (18 hours) infusion in primary PCI, from June 2009 to June 2011, at a single cardiac centre. Detailed chart review of demographic and clinical characteristics, times to intervention, complications, electrocardiographic (ECG) findings, bleeding, ejection fraction (EF), and stent thrombosis data was performed. Descriptive statistics were utilized to outline safety and efficacy outcomes. A p-value <0.05 was considered significant.
RESULTS
There was no significant difference between the two groups in complications including GI bleeding, hematoma larger than 5 cm, fistula or pseudo-aneurysm, retroperitoneal hemorrhage (RPH) or hemoglobin drop more than 50 g/L. Closure devices were deployed more in abbreviated infusion (65% vs. 44%, p-value: 0.004). There was a trend towards improved ST elevation resolution > 50% in standard infusion (78% vs. 66%, p-value: 0.06) and CK peaked higher in abbreviated infusion (2088.9 þ/-1982 vs. 1565 þ/-1545, p-value; 0.05). There was no significant difference in stent thrombosis or EF (47.25% þ/-9.46 vs. 49.4% þ/-9.2 for abbreviated and standard infusion respectively, p-value: 0.12). There was no significant difference in transfusion (3% vs. 5% for abbreviated and standard infusion respectively, p-value: 0.44) or death (3.2% vs. 1.1% for abbreviated and standard infusion respectively, p-value: 0.37).
CONCLUSIONS Abbreviated duration glycoprotein IIb/IIIa inhibition may be a safe and novel alternative to standard infusion during STEMI. Although there was no significant difference in bleeding or vascular complications between abbreviated and standard infusion groups, along with a trend towards better ST resolution and lower CK in standard infusion group, but there was no significant difference in stent thrombosis, EF or death between the two groups. Further large prospective randomized controlled trials are indicated to study this approach to reduce bleeding in this high risk population.
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Clinical Outcomes Of Drug-eluting Stents Implantation In Octogenarians: Difference In ST-And Non-ST-segment Elevation Myocardial Infarction
